Somnomed Ltd traded at 0.61 this Friday February 6th, decreasing 0.03 or 3.97 percent since the previous trading session. Looking back, over the last four weeks, Somnomed lost 19.87 percent. Over the last 12 months, its price fell by 6.20 percent. Looking ahead, we forecast Somnomed Ltd to be priced at 0.66 by the end of this quarter and at 0.62 in one year, according to Trading Economics global macro models projections and analysts expectations.
SomnoMed Limited is an Australia-based company, which is engaged in producing and selling devices for the oral treatment of sleep-related disorders, primarily in the Asia Pacific region, North America and Europe. The Company provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is focused on the commercialization of the SomnoDent and other oral devices for sleep-related disorders. Its SomnoDent product line includes signature line products, such as Avant, Herbst Advance Elite, Fusion, Flex and Classic; standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. It also manufactures custom fit acrylic occlusal splints (dental guards), the SomnoBrux, to protect patients teeth against heaving grinding and bruxism. The Company provides SomGauge , which is an autoclavable instrument which can be used to construct accurate and reliable bite records. It also offers compliance recorder.